Terms and Conditions

Healthcare Professional Participation in DAXXIFY® Patient “Your Turn” Limited Time Offers

Effective and Available:

Customer Buy-in Period: February 1, 2024 – March 1, 2024

Patient Reward Redemption Period:
February 1, 2024 – April 30, 2024

The DAXXIFY® Patient Reward Limited Time Offer (the "Offer"), owned and operated by Revance Therapeutics, Inc. ("Revance," "we," "us" or "our") is made available to consumers interested in treatment with DAXXIFY®. As a healthcare professional (“HCP,” "you," "your," or "user") you may participate in the Offer under the following terms and conditions, including the amendments thereto and with any additional terms and conditions, rules, or polices that may be applicable in connection with the Offer (collectively, the "Terms and Conditions"). Your failure to follow the Offer's rules, whether listed below or in supplemental notices posted at various points in the Offer, may result in termination of your access and ability to participate in the Offer, without notice, in addition to Revance’s other remedies. Your participation in, access to, and use of the Offer are subject to the terms and conditions set forth herein and all applicable laws and regulations, including the laws and regulations governing copyrights and trademarks. The Terms and Conditions shall supersede all previous Offer rules and/or terms and conditions applicable to healthcare professionals. The following Terms and Conditions may be modified by Revance from time to time, without advanced notice. Any such changes shall be reflected in an updated version of the Terms and Conditions. BY PARTICIPATING AND ACCESSING THE OFFER, YOU ACCEPT, WITHOUT LIMITATION OR QUALIFICATION, ALL OF THE TERMS AND CONDITIONS OF THE OFFER.

I. Description of Patient Offer:

The patient Offer is a text, mobile device-based Offer where registered eligible users of the Offer may receive an instant $75.00 discount off of a DAXXIFY® aesthetics treatment (“Discount”). The Offer is not applicable for therapeutic uses of DAXXIFY®. You will receive a code which you will provide to the patient and the patient will send the code by text message to Revance to receive the Discount. You will apply the Discount to reduce the total cost of the patient’s DAXXIFY® treatment by $75.00. The Offer has no independent cash or monetary value and is not redeemable for cash, transferable or assignable for any reason, and cannot be sold, traded, bartered, auctioned through an online auction site or otherwise; any such Discount may be confiscated by Revance and/or cancelled. The Offer may be changed from time to time at Revance’s sole discretion without advance notice. Any change to the Offer or these Terms and Conditions will be posted on this site and by continuing to participate in the Offer, you are deemed to have agreed to the amended version of these Terms and Conditions and are bound by any such revisions and should therefore periodically visit this website to review the current Terms and Conditions to which you are bound.

II. Offer Eligibility for HCPs

The Offer is open to appropriately licensed HCPs in the United States. In order to participate in the Offer, an HCP must purchase a minimum of 50 vials of DAXXIFY® in a single order at the ship-to location during the promotion period. Upon meeting the minimum purchase requirement, for every vial of DAXXIFY® purchased, you will receive one $75.00 patient reward for one of your patients.

For example:

Number of DAXXIFY Vials Purchased During Promotion

Number of Patient Rewards Received

50 Vials of DAXXIFY® 

50 $75 Patient Discounts

100 Vials of DAXXIFY® 

100 $75 Patient Discounts

150 Vials of DAXXIFY® 

150 $75 Patient Discounts

In order to qualify, the vials of DAXXIFY® must be purchased directly from Revance. Accounts cannot apply previous purchases made before the Promotional dates. Practices cannot combine smaller orders to qualify. Practices with multiple locations cannot combine smaller orders made at different locations to qualify. Practice must purchase a minimum of 50 vials at the ship-to location. Only one Discount is available per patient during the promotion term.

The Offer is available for aesthetics treatments received by patients between February 1, 2024 and April 30, 2024. Void where prohibited or restricted by law.

III. Reservation of Rights

The Offer and its Discounts are offered at Revance’s discretion, and Revance has the right to modify or discontinue, temporarily or permanently, the Offer, including the Discounts offered, in whole or in part, for any reason, at our sole discretion. Revance may, among other options, withdraw, limit, modify, or cancel any Discount; change the value of any Discounts; increase the requirements for any Discount; or modify or condition the redemption of Discounts. You agree that Revance will not be liable to you or any third party for any modification or discontinuance of the Offer or any Discount offered, in whole or in part.

IV. Earning and Redeeming Patient Offer Benefits

Patients will earn a Discount in the amount of $75.00 off of their treatment of DAXXIFY®. The HCP’s office must have made a qualifying purchase order to qualify – purchase a minimum of 50 vials or more at the ship-to location between February 1, 2024 through March 1, 2024. After making qualified purchases of DAXXIFY® as described above, you will receive patient Discount codes to provide patients which the patient will text to Revance. Once Revance confirms the code, the patient will be entitled to a $75.00 discount off of the patient’s treatment with DAXXIFY®.

Revance will reimburse the practice for each redeemed code that is affiliated with the practice through ACH to the practice’s account. Reimbursement payments will be made weekly and cover the codes that were redeemed in the previous week. Practices can redeem codes with eligible patients through April 30, 2024. After April 30 2024, unused codes will be null and void.

V. Use of Your Information and Personal Information

The information that you provide in connection with the Offer will be used by Revance in connection with the administration of the Offer and to provide you information about the Offer. Furthermore, Revance may use any information you provide for Revance’s internal purposes and to send you information about Revance and its products and services. Revance will not share your information with any third party, except as necessary for the administration of the Offer or as required by law or legal process. If you do not wish Revance to send information to you about the Offer and Revance and its products and services, you should not participate in the Offer. By participating in the Offer, you agree that we may collect and use personal information about you that you provide to us in accordance with our Privacy Policy which can be found at: https://www.revance.com/privacy-policy/. By using the Offer, you agree to be bound by the terms of our Privacy Statement.

VI. Fraud

Fraud or abuse relating to the accrual or redemption of Offer may result in forfeiture of your compensation under the Offer and ability to participate in the Offer in the future. IT WILL BE CONSIDERED FRAUDULENT AND A VIOLATION OF THESE TERMS AND CONDITIONS FOR YOU TO SEEK COMPENSATION FOR REDEEMING BENEFITS THAT WERE NOT PROPERLY EARNED OR REDEEMED.

VII. Limitation of Liability; Release

Revance and its affiliates and their respective representatives, agents, directors, officers, shareholders, and employees (“Revance Entities”) are not responsible for and shall not be liable for: (i) late, lost, delayed, damaged, misdirected, inaccurate, incomplete, or unintelligible entries, submissions, or materials supplied in connection with Discounts; (ii) any injuries, losses, or damages of any kind arising in connection with or as a result of the Discount, delivery or failure to timely deliver, possession, or use of the Discount, or from participation in the Offer; or (iii) any printing or typographical errors in any materials associated with the Offer. Further, in no event shall the Revance Entities be liable for any damages of any kind or nature, including but not limited to, direct, indirect, incidental, consequential, exemplary, special (including loss or profit), punitive, or other damages arising from or in connection with the existence or use of the Offer or any such dispute, regardless of whether any of the Revance Entities has been advised as to the possibility of such damages.

VIII. Violation of the Terms and Conditions

You understand and agree that in our sole discretion, and without prior notice, we may terminate your access to the Offer if we determine that you have violated our Terms and Conditions.

IX. Proprietary Rights

You should assume that all contents of this site are copyrighted unless otherwise noted and may not be used except as provided herein and without our express written permission. Except as expressly provided herein, nothing contained herein shall be construed as conferring any license or right under any Revance copyright. All product names, logos, and service marks displayed on this site that are identified by ® or ™ or appearing in type form different from that of the surrounding text (collectively, the “Trademarks”) are registered or unregistered trademarks owned by or licensed to Revance or our affiliates, unless otherwise identified as being owned by another entity. Nothing contained herein shall be construed as conferring by implication, estoppel, or otherwise any license or right, either express or implied, under any patent or Trademark of Revance or any third party. No use of any Trademark may be made without our prior written authorization.

X. Governing Law and Disputes

These Terms and Conditions shall be governed by and construed in accordance with the laws of the State of California without regard to choice of law principles. You agree that any dispute related to the Offer shall be submitted for resolution exclusively to the jurisdiction of the United States District Court of California. All applicable federal, state, and local laws and regulations apply. The invalidity or unenforceability of any provisions of these Terms and Conditions shall not affect the validity or enforceability of any provision. In the event that any provision of these Terms and Conditions is found to be invalid or unenforceable, these Terms and Conditions shall be construed in accordance with their terms as if the invalid or unenforceable provision was not contained therein.


Offer DAXXIFY® to Your Patients

Learn how to order today.

Get Started

WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than glabellar lines.

INDICATION DAXXIFY® (daxibotulinumtoxinA-Ianm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.


DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Drug Interactions
Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations
DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.



  1. 1. Data on File. D220801001. Newark, CA: Revance Therapeutics, Inc, 2022.
  2. 2. Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82(4):838-845. doi:10.1016/j.jaad.2019.06.1313.
  3. 3. Data on File. D231201010. Newark, CA: Revance Therapeutics, Inc, 2023.
  4. 4. BOTOX® Cosmetic. Prescribing Information. Allergan Inc; 2023.
  5. 5. XEOMIN®. Prescribing Information. Merz Pharmaceuticals GmbH; 2021.
  6. 6. DYSPORT®. Prescribing Information. Ipsen Biopharmaceuticals, Inc.; 2023.
  7. 7. JEUVEAU®. Prescribing Information. Evolus, Inc; 2020.
  8. 8. DAXXIFY®. Prescribing Information. Revance Therapeutics, Inc; 2022.
  9. 9. Data on File. The Harris Poll Facial Injectables Landmark Survey Results. Newark, CA: Revance Therapeutics, Inc, 2018.
  10. 10. Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58.
  11. 11. Pulkoski-Gross MJ, Fang C, Shai R, Too P. A cell-penetrating peptide binds directly to and enhances membrane binding of the core toxin of botulinum toxin type A (BoNTA). Poster presented at: TOXINS 2022; July 27-30, 2022; New Orleans, LA.
  12. 12. Solish N, Carruthers J, Kaufman J, Rubio R, Gross T, Gallagher C. Overview of DaxibotulinumtoxinA for Injection: a novel formulation of botulinum toxin type A. Drugs. 2021;81:2091-2101.
  13. 13. Fabi SG, Cohen JL, Green LJ, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. Dermatol Surg. 2020;47(1):48-54. doi:10.1097/DSS.0000000000002531t.
  14. 14. Green JB, Mariwalla K, Coleman K, et al. A large, open-label, phase 3 safety study of daxibotulinumtoxinA for injection in glabellar lines: a focus on safety from the SAKURA 3 study. Dermatol Surg. 2021;47(1):42-46. doi:10.1097/DSS.0000000000002463.
  15. 15. Brown J, Stephenson J, Kooken K, Sparrow J. Impact of DaxibotulinumtoxinA for Injection on skin smoothness following treatment of glabellar lines. Poster presented at: Derm2023 NP/PA CME Conference; August 3-6, 2023; Las Vegas, NV.
  16. 16. Data on File. Gross. American Academy of Dermatology. Newark, CA: Revance Therapeutics, Inc, 2021.
  17. 17. Data on File. Sak_1_and_Sak_2_facial paresis-asymmetry. Newark, CA: Revance Therapeutics, Inc, 2018.
  18. 18. Data on File. D220801002. Newark, CA: Revance Therapeutics, Inc, 2021.

©2024 REVANCE AESTHETICS. DAXXIFY, Revance Therapeutics, and the Revance logo are registered trademarks of Revance Therapeutics, Inc. All other trademarks are the property of their respective owners.
DX00255 DAXI-001856.3